Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retinal haemorrhage24.07.05.003; 06.10.01.0010.000087%Not Available
Retinopathy24.03.07.003; 06.10.02.0010.000035%
Retroperitoneal fibrosis20.06.01.006; 10.02.01.026; 07.07.03.0030.000035%Not Available
Retroperitoneal haemorrhage07.07.02.002; 12.01.17.018; 24.07.01.0170.000087%
Rhabdomyolysis15.05.05.0020.000262%
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.000245%Not Available
Rhythm idioventricular02.03.04.0190.000070%Not Available
Rickets15.02.03.006; 14.04.04.0050.000035%Not Available
Rotator cuff syndrome12.01.07.018; 15.01.08.0020.000070%
Salivary hypersecretion07.06.01.0090.000070%Not Available
Sarcoidosis10.02.06.0010.000052%Not Available
Scab23.03.03.0040.000052%Not Available
Sciatica17.10.03.001; 15.10.01.0010.000087%Not Available
Scleritis10.02.01.025; 06.04.07.0020.000122%Not Available
Scoliosis15.10.04.0010.000035%
Screaming08.01.03.099; 19.04.02.0200.000112%Not Available
Seborrhoea23.02.07.0010.000035%Not Available
Seborrhoeic keratosis23.10.01.008; 16.26.01.0080.000136%Not Available
Secondary adrenocortical insufficiency14.11.01.014; 05.03.04.0120.000297%Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.0070.000087%Not Available
Shock24.06.02.0020.000192%Not Available
Sinus bradycardia02.03.03.0090.000070%
Sinus tachycardia02.03.03.0100.000245%
Sjogren's syndrome06.08.02.011; 15.06.01.015; 10.04.04.009; 07.06.01.0100.000070%Not Available
Skin atrophy23.01.05.0010.000140%
Skin depigmentation23.05.02.0020.000052%Not Available
Skin disorder23.03.03.0070.000192%Not Available
Skin erosion23.07.03.0020.000105%Not Available
Skin fragility23.03.03.0090.000052%Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene